

Effective In Vitro and In Vivo Gene Delivery by the Combination of Liposomal Bubbles




Fig. 4. In vivo gene delivery into mouse ascites tumor cells with Bubble liposomes. S-180 cells (1×10^6 cells) were i.p. injected into ddY mice. After 8 days, the mice were anaesthetized, then injected with 510 μ L of pCMV-Luc (10 μ g) and Bubble liposomes (500 μ g) in PBS. Ultrasound (frequency: 1 MHz, duty: 50%; intensity: 1.0 W/cm², time: 1 min) was transdermally applied to the abdominal area. In another experiment, pCMV-Luc (10 μ g) – Lipofectin (50 μ g) or Lipofectamine 2000 (50 μ g) complex was suspended in PBS (510 μ L) and injected into the peritoneal cavity of mice. After 2 days, S-180 cells were recovered from the abdomens of the mice. Luciferase activity was determined, as described in Materials and Methods. Each bar represents the mean \pm S.D. ($n=3-6$). ** $P < 0.01$ compared to the group treated with plasmid DNA, Bubble liposomes, ultrasound exposure or lipofection with Lipofectin or Lipofectamine 2000. LF, Lipofectin. LF2000, Lipofectamine 2000. # $< 10^2$ RLU/mg protein

4. After 2 days of US exposure, ascites tumor cells were recovered from the abdomen of the mice. Then, the gene expression in the recovered cells was measured (see Fig. 5). 234
235
236

3.5.3. Gene Delivery for Solid Tumor (20)

1. S-180 cells (1×10^6 cells) were inoculated into the left footpad of ddY mice (5 weeks age, male). 237
238
2. At day 4, when the thickness of the footpad was over 3.5 mm (normal thickness was about 2 mm), the left femoral artery was exposed by operation. 239
240
241
3. BLs (100 μ g) and plasmid DNA suspension (100 μ L) were injected into the femoral artery using 30-gauge needle. 242
243
4. In the same time, US (frequency: 0.7 MHz, duty: 50%, intensity: 1.2 W/cm², time: 2 min) was transdermally exposed to the tumor tissue using Sonopore 3000 or 4000 with a probe (KP-T8) (diameter: 8 mm). 244
245
246
247
5. The needle hole was then closed with an adhesive agent and skin was put in a suture. 248
249

Suzuki and Maruyama




Fig. 5. Gene delivery to femoral artery with Bubble liposomes Each sample containing plasmid DNA 10 μ g was injected into femoral artery. At the same time, ultrasound (frequency, 1 MHz; duty, 50%; burst rate, 2 Hz; intensity, 1 W/cm²; time 2 min) was exposed to the downstream area of injection site. (a) Luciferase expression in femoral artery of the ultrasound exposure area at 2 days after transfection, Luciferase expression was determined as described in Materials and Methods. Data are shown as means \pm S.D. ($n=5$). (LF2000: Lipofectamine 2000) (b) In vivo luciferase imaging at 2 days after transfection in the mouse treated with plasmid DNA, Bubble liposomes and ultrasound exposure. The photon counts are indicated by the pseudocolor scales




Fig. 6. In vivo gene delivery into mouse solid tumor with Bubble liposomes. S-180 cells (1×10^6 cells) were inoculated into left footpad of ddY mice. After 4 days, the mice were anaesthetized, then injected with 100 μ L of pCMV-Luc (10 μ g) in absence or presence of Bubble liposomes (100 μ g) in PBS. Ultrasound (frequency: 0.7 MHz, duty: 50%; intensity: 1.2 W/cm², time: 1 min) was transdermally exposed to tumor tissue. In another experiment, pCMV-Luc (10 μ g) – Lipofectamine 2000 (25 μ g) complex was suspended in PBS (100 μ L) and injected into the left femoral artery. After 2 days, tumor tissue was recovered from the mice. Luciferase activity was determined as described in Materials and Methods. (a) Luciferase activity in solid tumor. Each bar represents the mean \pm S.D. for five mice/group. ** $P < 0.01$ compared to the group treated with plasmid DNA, ultrasound exposure or Lipofectamine 2000. (b) In vivo luciferase imaging in the solid tumor bearing mice. The photon counts are indicated by the pseudocolor scales. LF 2000, Lipofectamine 2000

250
251
252

6. After 2 days of US exposure, the mice were sacrificed and the tumor tissues were collected. Then, the gene expression of the tumor tissue was measured (see Fig. 6 and Note 8).

Effective In Vitro and In Vivo Gene Delivery by the Combination of Liposomal Bubbles

3.6. Measurement of Reporter Gene Expression		
3.6.1. Luciferase Assay	1. The lysis buffer (0.1 M Tris-HCl (pH 7.8), 0.1% Triton X-100, 2 mM EDTA) was added to the sample cells in vitro or tissues in vivo. In the case of the tissues in vivo, they were homogenized before next step.	253 254 255 256
	2. The cells or the homogenized tissues in lysis buffer were repeatedly frozen and thawed three times to completely disrupt the cell membranes.	257 258 259
	3. After that, the lysate of the cells or tissues was centrifuged and the supernatant was collected in other tube.	260 261
	4. Luciferase activity in the supernatant was measured using a luciferase assay system and a luminometer. The activity is reported in relative light units (RLU) per mg protein of cells or tissue.	262 263 264 265
3.6.2. In Vivo Luciferase Imaging	1. The mice were anaesthetized with Escain and i.p. injected with D-luciferin (150 mg/kg).	266 267
	2. After 10 min, luciferase expression was observed with in vivo luciferase imaging system (IVIS).	268 269

4. Notes 270

1. There are some important points to prepare BLs. The air in the vial containing the liposome suspension is completely replaced with perfluoropropane. After that, it needs to be supercharged in the vial with perfluoropropane. And the vial is sonicated with a bath-type sonicator (42 KHz, 100 W) (BRANSONIC 2510 J-DTH, Branson Ultrasonics). In this step, sonication power and the vial position in the bath are very important. Because we have experimented that BLs were not prepared using other type of bath sonicator (UC-1 (38 KHz, 80 W), IKEDA RIKKA, Japan) with low intensity of ultrasound exposure. In addition, BLs were not prepared using other gas such as air, nitrogen gas or carbonic dioxide gas. Therefore, it thought that it is important for the preparation of BL to use hydrophobic gas such as perfluoropropane.	271 272 273 274 275 276 277 278 279 280 281 282 283 284
2. To fix BLs as a sample for transmission electron microscope, BLs were held within calcium alginate gel. The handling of BLs was improved by holding within the gel. The advantage for using this gel is to make the gel even at low temperature. Because BLs became unstable according to increasing temperature. Therefore, it is thought that the gel, such as agarose, which has gel point at high temperature is inappropriate for this purpose.	285 286 287 288 289 290 291 292
3. It was thought that liposomes were reconstituted by sonication under the condition of supercharge with perfluoropropane.	293 294

Suzuki and Maruyama

- 295 Then, perfluoropropane was entrapped within lipids like
296 micelles. In addition, the lipid nanobubbles were encapsu-
297 lated within liposomes. To confirm the structure of BLs, we
298 observed BLs with transmission electron microscope.
299 Interestingly, BLs had nanobubbles into lipid bilayer.
300 Therefore, we called this “Bubble liposome” because of this
301 structure. This structure of BLs was different from that of
302 conventional microbubbles and nanobubbles which had lipid
303 monolayer.
- 304 4. This protocol can be adapted for many other types of cell. In
305 the gene transfection for adherent cells, the transfection effi-
306 ciency in the condition of suspension was higher than that in
307 the condition of adhesion on the culture plate. Although this
308 result is unclear, it is thought that the distance between BLs
309 and cells is important. Because BLs entrapping gas is easy to
310 flow and result in getting away from the adherent cells on
311 the plate.
- 312 5. In in vitro gene delivery, it is very important to fix the loca-
313 tion of it, in order to reduce the experimental error of each
314 data. The efficiency of this gene delivery was not affected
315 even in the presence of serum. Moreover, the gene expression
316 was observed even under the condition of US exposure for
317 1 s. From these results, it was suggested that this system could
318 immediately deliver plasmid DNA into cells.
- 319 6. In in vivo gene delivery, echo jelly is necessary for US expo-
320 sure to mice. Gene expression was observed in the arrested
321 area of US exposure. Because it is thought that the mechani-
322 cal effect based on the disruption of BLs by US exposure
323 results in generation of some pores on plasma membrane of
324 the cells in the area of US exposure.
- 325 7. This system is thought that there is not a serious damage for
326 the cells in blood such as red blood cells by the disruption of
327 BLs in blood stream by US exposure.
- 328 8. The transfection efficiency with the gene delivery system by
329 sonoporation mechanism using BLs and US was higher
330 than conventional lipofection method with Lipofectin and
331 Lipofectamine 2000. Therefore, it is expected that this sys-
332 tem might be an effective nonviral gene delivery system.

333 Acknowledgements

334 We are grateful to Dr. Katsuro Tachibana (Department of
335 Anatomy, School of Medicine, Fukuoka University) for technical
336 advice regarding the induction of cavitation with ultrasound,
337 to Dr. Naoki Utoguchi, Mr. Yusuke Oda, Mr. Eisuke Namai,

Effective In Vitro and In Vivo Gene Delivery by the Combination of Liposomal Bubbles

338 Ms. Tomoko Takizawa, Ms. Kaori Sawamura and Ms. Kumiko
 339 Tanaka (Department of Pharmaceutics, School of Pharmaceutical
 340 Sciences, Teikyo University), Yoichi, Negishi (School of
 341 Pharmacy, Tokyo University of Pharmacy and Life Science), and
 342 Dr. Kosuke Hagsawa (Department of Medical Engineering,
 343 National Defense Medical College) for excellent technical advice
 344 and assistance, to Mr. Yasuhiko Hayakawa, Mr. Takahiro
 345 Yamauchi, and Mr. Kosho Suzuki (NEPAGENE Co., Ltd.) for
 346 technical advice regarding ultrasound exposure using Sonopore
 347 3000 and 4000, and Sonitron 2000.

348 This study was supported by an Industrial Technology
 349 Research Grant in 2004 from NEDO, JSPS KAKENHI
 350 (16650126), MEXT KAKENHI (160700392, 19700423), a
 351 Research on Advanced Medical Technology (17070301) in
 352 Health and Labour Sciences Research Grants from Ministry of
 353 Health, Labour and Welfare, and the Program for Promotion of
 354 Fundamental Studies(07-24) in Health Sciences of the National
 355 Institute of Biomedical Innovation (NIBIO).

356 References

- 357 1. Fechheimer M, Boylan JF, Parker S, Sicken JE, Patel GL, Zimmer SG (1987) Transfection of
 358 mammalian cells with plasmid DNA by scrape
 359 loading and sonication loading. *Proc Natl
 360 Acad Sci U S A* 84:8463-8467
- 362 2. Miller MW, Miller DL, Brayman AA (1996) A
 363 review of in vitro bioeffects of inertial ultra-
 364 sonic cavitation from a mechanistic perspec-
 365 tive. *Ultrasound Med Biol* 22:1131-1154
- 366 3. Joersbo M, Brunstedt J (1990) Protein syn-
 367 thesis stimulated in sonicated sugar beet cells
 368 and protoplasts. *Ultrasound Med Biol*
 369 16:719-724
- 370 4. Miller DL, Pislaru SV, Greenleaf JE (2002)
 371 Sonoporation: mechanical DNA delivery by
 372 ultrasonic cavitation. *Somat Cell Mol Genet*
 373 27:115-134
- 374 5. Guzman HR, McNamara AJ, Nguyen DX,
 375 Prausnitz MR (2003) Bioeffects caused by
 376 changes in acoustic cavitation bubble density
 377 and cell concentration: a unified explanation
 378 based on cell-to-bubble ratio and blast radius.
 379 *Ultrasound Med Biol* 29:1211-1222
- 380 6. Wei W, Zheng-zhong B, Yong-jie W, Qing-wu Z,
 381 Ya-lin M (2004) Bioeffects of low-frequency
 382 ultrasonic gene delivery and safety on cell mem-
 383 brane permeability control. *J Ultrasound Med*
 384 23:1569-1582
- 385 7. Duvshani-Eshet M, Machluf M (2005)
 386 Therapeutic ultrasound optimization for gene
 387 delivery: a key factor achieving nuclear DNA
 388 localization. *J Control Release* 108:513-528
8. Tata DB, Dunn F, Tindall DJ (1997) Selective
 389 clinical ultrasound signals mediate differential
 390 gene transfer and expression in two human
 391 prostate cancer cell lines: LnCap and PC-3.
 392 *Biochem Biophys Res Commun* 234:64-67
 393
9. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT,
 394 Bolander ME (1996) Ultrasound-mediated
 395 transfection of mammalian cells. *Hum Gene
 396 Ther* 7:1339-1346
 397
10. Greenleaf WJ, Bolander ME, Sarkar G,
 398 Goldring MB, Greenleaf JF (1998) Artificial
 399 cavitation nuclei significantly enhance acousti-
 400 cally induced cell transfection. *Ultrasound
 401 Med Biol* 24:587-595
 402
11. Shohet RV, Chen S, Zhou YT, Wang Z,
 403 Meidell RS, Unger RH, Grayburn PA (2000)
 404 Echocardiographic destruction of albumin
 405 microbubbles directs gene delivery to the
 406 myocardium. *Circulation* 101:2554-2556
 407
12. Taniyama Y, Tachibana K, Hiraoka K, Namba
 408 T, Yamasaki K, Hashiya N, Aoki M, Ogihara T,
 409 Yasufumi K, Morishita R (2002) Local delivery
 410 of plasmid DNA into rat carotid artery using
 411 ultrasound. *Circulation* 105:1233-1239
 412
13. Taniyama Y, Tachibana K, Hiraoka K, Aoki M,
 413 Yamamoto S, Matsumoto K, Nakamura T,
 414 Ogihara T, Kaneda Y, Morishita R (2002)
 415 Development of safe and efficient novel nonviral
 416 gene transfer using ultrasound: enhance-
 417 ment of transfection efficiency of naked
 418 plasmid DNA in skeletal muscle. *Gene Ther*
 419 9:372-380
 420

Suzuki and Maruyama

- 421 14. Sonoda S, Tachibana K, Uchino E, Okubo A, 444
422 Yamamoto M, Sakoda K, Hisatomi T, Sonoda 445
423 KH, Negishi Y, Izumi Y, Takao S, Sakamoto T 446
424 (2006) Gene transfer to corneal epithelium 447
425 and keratocytes mediated by ultrasound with 448
426 microbubbles. *Invest Ophthalmol Vis Sci* 449
427 47:558–564 450
- 428 15. Newman CM, Bettinger T (2007) Gene ther- 451
429 apy progress and prospects: ultrasound for 452
430 gene transfer. *Gene Ther* 14:465–475 453
- 431 16. Lindner JR (2004) Microbubbles in medical 454
432 imaging: current applications and future direc- 455
433 tions. *Nat Rev Drug Discov* 3:527–532 456
- 434 17. Tsunoda S, Mazda O, Oda Y, Iida Y, Akabame 457
435 S, Kishida, T, Shin-Ya M, Asada H, Gojo S, 458
436 Imanishi J, Matsubara H, Yoshikawa T (2005) 459
437 Sonoporation using microbubble BR14 pro- 460
438 motes pDNA/siRNA transduction to murine 461
439 heart. *Biochem Biophys Res Commun* 462
440 336:118–127 463
- 441 18. Suzuki R, Takizawa T, Negishi Y, Hagsawa K, 464
442 Tanaka K, Sawamura K, Utoguchi N, Nishioka 465
443 T, Maruyama K (2007) Gene delivery by 466
combination of novel liposomal bubbles with
perfluoropropane and ultrasound. *J Control
Release* 117:130–136
19. Suzuki R, Takizawa T, Negishi Y, Utoguchi
N, Maruyama K (2007) Effective gene deliv-
ery with liposomal bubbles and ultrasound as
novel non-viral system. *J Drug Target*
15:531–537
20. Suzuki R, Takizawa T, Negishi Y, Utoguchi
N, Sawamura K, Tanaka K, Namai E, Oda Y,
Matsumura Y, Maruyama K (2008) Tumor
specific ultrasound enhanced gene transfer in
vivo with novel liposomal bubbles. *J Control
Release* 125:137–144
21. Suzuki R, Takizawa T, Negishi Y, Utoguchi
N, Maruyama K (2008) Effective gene deliv-
ery with novel liposomal bubbles and ultra-
sonic destruction technology. *Int J Pharm*
354:49–55
22. Mosmann T (1983) Rapid colorimetric assay
for cellular growth and survival: application to
proliferation and cytotoxicity assays. *J
Immunol Methods* 65:55–63

Author Query

Chapter No.: 33 0001095075

Query	Details Required	Author's Response
AU1	Please check if the editing does not change the meaning.	

Uncorrected Proof

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Synergistic effect of ultrasound and antibiotics against *Chlamydia trachomatis*-infected human epithelial cells in vitro

Yurika Ikeda-Dantsuji^a, Loreto B. Feril Jr.^{a,*}, Katsuro Tachibana^a, Koichi Ogawa^a, Hitomi Endo^a, Yoshimi Harada^a, Ryo Suzuki^b, Kazuo Maruyama^b

^a Department of Anatomy, Fukuoka University School of Medicine, Fukuoka, Japan

^b Department of Biopharmaceutics, School of Pharmaceutical Sciences, Teikyo University, Kanagawa, Japan

ARTICLE INFO

Article history:

Received 12 April 2010

Received in revised form 12 July 2010

Accepted 21 July 2010

Available online 27 July 2010

Keywords:

Ultrasound

Nanobubbles

Antibiotic

Intracellular bacteria

ABSTRACT

To investigate whether or not the combined ultrasound and antibiotic treatment is effective against chlamydial infection, a new ultrasound exposure system was designed to treat chlamydia-infected cells. First, the minimum inhibitory concentrations of antibiotics against *Chlamydia trachomatis* were determined. Infected cultures were treated with antibiotics then sonicated at intensity of 0.15 or 0.44 W/cm² with or without Bubble liposomes. After 48 or 72 h after infection, chlamydial inclusions were stained and examined by fluorescence microscopy. The internalization of dextran–fluorescein conjugates by ultrasound irradiation with Bubble liposomes was observed by fluorescence microscopy. The results showed that application of nanobubble-enhanced ultrasound caused no significant effect on cell viability and chlamydial infectivity. However, Doxycycline (1/2 MIC) or CZX (1.0 µg/ml) in combination with nanobubble-enhanced ultrasound dramatically reduced the number of inclusions compared with that administered with antibiotics only. Bubble dose-dependent synergy was also observed. After ultrasound irradiation at intensity of 0.44 W/cm² on the presence of Bubble liposomes, 10% of HeLa cells were observed to have internalized the dextran molecules. This study suggests the possibility of using nanobubble-enhanced ultrasound to deliver antibiotic molecules into cells to eradicate intracellular bacteria, such as chlamydiae, without causing much damage to the cells itself.

© 2010 Elsevier B.V. All rights reserved.

1. Introduction

An obligate intracellular pathogen, *Chlamydia trachomatis*, is the most prevalent sexually transmitted bacterium worldwide [1]. *C. trachomatis* is a Gram-negative bacterium which has a unique biphasic developmental cycle characterized by an infectious but metabolically inactive extracellular form, called the ‘elementary body’, which initiates infection through the uptake by the host cell. Thereafter, elementary bodies differentiate into noninfectious but metabolically active forms, called the ‘reticulate body’, which proliferate within the inclusion. Reticulate bodies also differentiate back to elementary bodies before release at the end of the developmental cycle. At its sites of primary infection, *C. trachomatis* infects the urethral or cervical epithelium, causing acute urethritis or cervicitis [2]. These frequently progress into chronic inflammatory disease, the most significant of which, is chronic salpingitis, an inflammatory disease of fallopian tubes that can result in pelvic inflammatory disease, ectopic pregnancy, and tubal infertility [3].

The recommended antibiotic treatments for urogenital infections are a single dose of azithromycin or a 7-day course of doxycycline for management of active infections [4]. These regimens have been shown to result in satisfactory cure rates of acute infections [5,6]; however, chronic diseases (designated “persistent infection”) have been suggested to be less responsive to antibiotic therapy [7].

Previous work has shown that some antibiotics treatment of *Pseudomonas aeruginosa* or *Escherichia coli* coupled with ultrasound irradiation enhances the bactericidal activity [8]. The more recent research has revealed that similar synergistic effects of combined ultrasound and antibiotic treatment are seen in both Gram-positive and Gram-negative bacteria with some antibiotics, especially the aminoglycosides [9]. It is not clear whether the combined ultrasound and antibiotic treatment are effective on intracellular pathogen, e.g. chlamydial infection. If an intracellular bacterial infection could be efficiently eradicated from an infected person, one could avoid chronic antibiotic treatments. In addition, this strategy of treatment could be beneficial in the management of chlamydial persistent diseases.

Here, we are studying the synergistic use of ultrasound and antibiotics to kill the *chlamydia*. This report presents results of

* Corresponding author. Address: 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180 Japan. Tel.: +81 92 801 1011x3206; fax: +81 92 865 6032.

E-mail addresses: ferilism@yahoo.com, feril@fukuoka-u.ac.jp (L.B. Feril).

the first step in that research, which is investigation of the in vitro response of *C. trachomatis*-infected human epithelial cells to combination of ultrasound and two types of antibiotics.

2. Materials and methods

2.1. Chlamydial strain and cell lines

C. trachomatis serovar E/UW-5/Cx was prepared in McCoy cells and propagated according to a previously reported method [10]. The mouse fibroblast cell line McCoy cell (CRL 1696) and human epithelial cell line HeLa 229 cell (CLL 2.1) were maintained in Dulbecco's modified Eagle medium (DMEM, Invitrogen, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (FCS, Invitrogen) and 100 µg/ml streptomycin.

2.2. Infection of HeLa cells

The HeLa cells were seeded into a 24-well plate with lumox™ fluorocarbon film base (optically clear, 50 µm-thin, gas permeable film, Greiner bio-one, Göttingen, Germany). Stocks of chlamydial strain were diluted with sucrose-phosphate-glutamate (SPG) medium [10]. Chlamydial suspensions of 0.5×10^4 inclusion-forming units (IFUs) in 0.25 ml SPG medium were inoculated onto the monolayer cultures of HeLa cells (1×10^4 cells/well). This is equivalent to a multiplicity of infection of 0.5. After incubation at 37 °C for 90 min, the inoculum was decanted, and the cells were washed in medium to remove the nonadsorbed chlamydiae and were then further incubated in 1 ml DMEM containing 1 µg/ml cycloheximide (Sigma Chemicals, St. Louis, MO, USA) and 2% FCS (maintenance medium).

2.3. Preparation of bubble liposome

Bubble liposomes were prepared according to a method previously described [11]. Liposomes composed of 1,2-distearoyl-sn-glycero-phosphatidylcholine (DSPC) (NOF Corp., Tokyo, Japan) and 1,2-distearoyl-sn-glycero-3-phosphatidyl-ethanolamine-methoxy polyethyleneglycol (DSPE-PEG(2k)-OME, (PEG Mw = ca. 2000), NOF) (94: 6 (m/m)) were prepared by reverse phase evaporation. Briefly, all reagents (total lipid: 100 µmol) were dissolved in 8 ml of 1:1 (v/v) chloroform/diisopropyl ether, then 4 ml of phosphate buffered saline (PBS) were added. The mixture was sonicated and evaporated at 65 °C. The solvent was completely removed, and the size of the liposomes was adjusted to less than 200 nm using an extruding apparatus (Northern Lipids Inc., Vancouver, BC, Canada) and sizing filters (pore sizes: 100 and 200 nm; Nuclepore Track-Etch Membrane, Whatman plc, UK). After sizing, the liposomes were sterilized by passing them through a 0.45 µm pore size filter (MILLEX HV filter unit, Durapore PVDF membrane, Millipore Corp., MA, USA). The size of the liposomes was measured by dynamic light scattering (ELS-800, Otsuka Electronics Co., Ltd., Osaka, Japan). The average diameter of these liposomes was between 150 and 200 nm. Lipid concentration was measured using the Phospholipid C test (Wako Pure Chemical Industries). BLs were prepared from the liposomes and perfluoropropane gas (Takachiho Chemical Industrial Co., Ltd., Tokyo, Japan). Briefly, 5 ml sterilized vials containing 2 ml of the liposome suspension (lipid concentration: 2 mg/ml) were filled with perfluoropropane, capped, and then supercharged with 7.5 ml of perfluoropropane. The vial was placed in a bath-type sonicator (42 kHz, 100 W; BRANSONIC 2510J-DTH, Branson Ultrasonics Co., Danbury, CT, USA) for 5 min to form the BLs. In this method, the liposomes were reconstituted by sonication under the condition of supercharge with perfluoropropane in the 5 ml vial container. At the same time, perfluoropropane would

be entrapped within lipids like micelles, which were made by DSPC and DSPE-PEG(2k)-OME from liposome composition, to form nanobubbles. The lipid nanobubbles were encapsulated within the reconstituted liposomes, which sizes were changed into around 1 µm from 150 to 200 nm of original.

2.4. Immunofluorescence staining and fluorescence microscopy

At 48 or 72 h after infection, the infected monolayers were washed with PBS, and the cells were fixed with -20 °C chilled methanol. After the specimens had been dried, the inclusion bodies were stained with fluorescein isothiocyanate (FITC)-labeled monoclonal antibody against *C. trachomatis* lipopolysaccharides (Progen Biotechnik, Heidelberg, Germany) for 30 min at room temperature. The cells were rinsed with saline, and the films were cut off from the plate, and mounted in a 1:1 solution of PBS-glycerol. The antibody staining resulted in yellow-green chlamydial proteins, and Evans blue counterstaining yielded red eukaryotic cells. The formation of inclusions was assessed using a Zeiss Axiophot fluorescence microscope. The cells positive for inclusions are considered infected cells and infectivity was presented as the number of inclusion-forming units (IFUs).

2.5. Antibiotics and measurements of MICs

Doxycycline (DOX, Sigma Chemicals) and ceftizoxime (CZX, Fujisawa Yakuhin Kogyo, Tokyo, Japan) were obtained in powder form. Both antibiotics were diluted with saline, and were dissolved in maintenance medium at a concentration of 100 µg/ml and frozen at -80 °C until used. The minimum inhibitory concentrations (MICs) were determined using a method previously described [12]. Briefly, confluent monolayer cultures of cells in a 24-well flat-bottomed plate with 13-mm coverslips were inoculated by centrifugation and incubated in 1 ml of maintenance medium containing a serial dilution of antibiotics for 72 h. To determine the MICs, the cover slips were stained and observed as described in immunofluorescence staining and fluorescence microscopy. The lowest concentration of the antimicrobial agent that completely inhibited the formation of visible chlamydial inclusions was determined as the MIC.

2.6. Ultrasound exposure

An acoustically transparent gel (Pharmaceutical Innovations Inc., Newark, NJ) was applied on the ultrasound probe before positioning the plate containing the sample on top of it (Fig. 1). Thera-




Fig. 1. Experimental design. Schematic drawing of the ultrasound setting. *C. trachomatis*-infected HeLa cells were exposed to ultrasound after addition of antibiotic and Bubble liposomes.